Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

    NEXT STORY
    Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
    PREV STORY
    NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    New Trump Administration Rules to Increase Patient Options Are Welcome Relief, States the Association of American Physicians and Surgeons (AAPS)

    TUCSON, Ariz., Aug. 02, 2018 (GLOBE NEWSWIRE) -- The Association of American Physicians and ...

    author_avatar
    NASDAQ Market News

    Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

    author_avatar
    NASDAQ Market News

    Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis

    ALPHARETTA, Ga., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News